Eosinophilic cellulitis induced by subcutaneous administration of interferon-β

Acta Dermato-Venereologica

Volumn 93, Issue 6, 2013, Pages 755-756

  Kambayashi, Yumi ^a   Fujimura, Taku ^a   Ishibashi, Masaya ^a   Haga, Takahiro ^a   Aiba, Setsuya ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CLOBETASOL PROPIONATE; DACARBAZINE; INTERLEUKIN 5; MELAN A; MONOCLONAL ANTIBODY HMB 45; NIMUSTINE; PROTEIN S 100; STAT1 PROTEIN; STAT6 PROTEIN; VINCRISTINE;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CASE REPORT; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LYMPHOCYTIC INFILTRATION; MALE; MEDICAL HISTORY; MELANOMA; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKIN BIOPSY; SKIN NODULE; TUMOR BIOPSY; TUMOR VOLUME; WELLS SYNDROME;

AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BIOPSY; CELLULITIS; DRUG ERUPTIONS; EOSINOPHILIA; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; PHOSPHORYLATION; STAT1 TRANSCRIPTION FACTOR; STAT6 TRANSCRIPTION FACTOR;

EID: 84886421126     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1611     Document Type: Article

References (10)

1. Winfield H, Lain E, Horn T, Hoskyn J. Eosinophilic cellulitis-like reaction to subcutaneous etanercept injection. Arch Dermatol 2006; 142: 218-220.
2. French LE, Shapiro M, Junkins-Hopkins JM, Wolfe JT, Rook AH. Eosinophilic fasciitis and eosinophilic cellulitis in a patient with abnormal circulating clonal T cells: increased production of interleukin 5 and inhibition by interferon alfa. J Am Acad Dermatol 2003; 49: 1170-1174.
3. Paul E, Müller I, Renner H, Bödeker RH, Cochran AJ. Treatment of locoregional metastases of malignant melanomas with radiotherapy and intralesional beta-interferon injection. Melanoma Res 2003; 13: 611-617.
4. Fujimura T, Okuyama R, Ohtani T, Ito Y, Haga T, Hashimoto A, et al. Perilesional treatment of metastatic melanoma with interferon-beta. Clin Exp Dermatol 2009; 34: 793-799.
5. Fujimura T, Yamasaki K, Hidaka T, Ito Y, Aiba S. A synthetic NOD2 agonist, muramyl dipeptide (MDP)-Lys (L18) and IFN-β synergistically induce dendritic cell maturation with augmented IL-12 production and suppress melanoma growth. J Dermatol Sci 2011; 62: 107-115.
6. Adamson AS, Collins K, Laurence A, O'Shea JJ. The current STATus of lymphocyte signaling: new roles for old players. Curr Opin Immunol 2009; 21: 161-166.
7. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77.
8. Chapoval S, Dasgupta P, Dorsey NJ, Keegan AD. Regulation of the T helper cell type 2 (Th2)/T regulatory cell (Treg) balance by IL-4 and STAT6. J Leukoc Biol 2010; 87: 1011-1018.
9. Zhu J, Jankovic D, Grinberg A, Guo L, Paul WE. Gfi-1 plays an important role in IL-2-mediated Th2 cell expansion. Proc Natl Acad Sci U S A 2006; 103: 18214-18219.
10. Nagai T, Devergne O, Mueller TF, Perkins DL, van Seventer JM, van Seventer GA. Timing of IFN-beta exposure during human dendritic cell maturation and naive Th cell stimulation has contrasting effects on Th1 subset generation: a role for IFN-beta-mediated regulation of IL-12 family cytokines and IL-18 in naive Th cell differentiation. J Immunol 2003; 171: 5233-5234.